Ainnocence is at the forefront of the biotechnology sector, leveraging advanced artificial intelligence to transform drug discovery processes. The company specializes in virtual screening, scientific intelligence, and molecular generative AI, which collectively aim to significantly reduce the risks and costs associated with drug development by up to 80%. By utilizing these innovative AI-driven systems, Ainnocence seeks to empower biotech and pharmaceutical companies to pursue ambitious research and development projects, including the exploration of previously undruggable targets and the expansion of drug intellectual property.

In addition to enhancing drug design, Ainnocence focuses on optimizing the drug discovery pipeline and rescuing failed clinical trials. Their approach not only aims to streamline the R&D process but also to foster a new era of scientific exploration, enabling the industry to tackle complex medical challenges with greater confidence. Through their commitment to integrating cutting-edge AI technologies, Ainnocence is poised to revolutionize the landscape of drug development and contribute to the advancement of healthcare solutions globally.

United States

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company's third-generation AI system delivers lightning-fast virtual screening and multi-objective pharmacological profile optimization for small-molecule, antibody, and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a shortlist of candidates with a very high wet-lab hit rate, and a dramatically reduced discovery time and cost. To learn more, visit ainnocence.com.

Ainnocence

Company Details